Dendreon Corp. is defending Provenge's position as the “foundation of care” for castration-resistant prostate cancer, following the recent approval of Johnson & Johnson’s Zytiga, and looking ahead to other novel drugs coming down the pike.

Dendreon Corp. is defending Provenge's position as the “foundation of care” for castration-resistant prostate cancer, following the recent approval of Johnson & Johnson’s Zytiga, and looking ahead to other novel drugs coming down the pike.

FDA’s speedy approval of Johnson & Johnson’s Zytiga (abiraterone) on April 28 – two months before the PDUFA date – paves the way for a third new advanced prostate cancer drug to get to market in a year and heralds the coming of even more competition in the valuable space.